PPMI launches new prodromal cohort

Recognizing the importance of understanding the earliest stages of disease and an opportunity to leverage the established infrastructure of the study, PPMI leadership has launched a new study arm to enroll and follow a prodromal Parkinson?s disease (PD) cohort. The goal of this additional cohort is to provide researchers with the opportunity to examine biomarker progression prior to the onset of motor symptoms. This new cohort seeks to enroll subjects without Parkinson?s disease who have at least one of the following characteristics: hyposmia, REM sleep behavior disorder, LRRK2 genetic mutation.   All subjects enrolled in this arm of PPMI will be age 60 and above, enriching for age which is perhaps the greatest risk factor for PD. None of these subjects will have PD. Specific recruitment tactics for the previously mentioned risk factors include:

Hyposmia: PPMI seeks 20,000 people to take a smell survey and then be smell tested using the UPSIT to determine their ability to smell. Those scored as being less than the 10th percentile will be invited to consent for the study.

RBD: Individuals with a diagnosis of RBD through a polysomnogram will be recruited through sleep centers at select PPMI sites and invited to consent for the study.

LRRK2: People who are 60 or older who do not have PD and know they have a LRRK2 mutation will be invited to participate. Genetic Counseling and testing will be available to those who are able to travel to the Boca Raton area and who are of Eastern European (Ashkenazi) Jewish descent.

To get more information, click here or review the updated protocol